Company · SNY
Sanofi
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
113
43 still marketed
Novel approvals
62
Approvals since 2021
24
Originals and new uses
Phase 3 trials
782
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Sarclisa Escena approved OrphanJul 9, 2026
- Cerezyme new use OrphanJan 12, 2026
- Wayrilz approved NovelOrphanAug 29, 2025
- Hectorol new use Jun 11, 2025
- Qfitlia approved NovelOrphanMar 28, 2025
- Merilog approved Feb 14, 2025
- Sarclisa new use OrphanOct 25, 2024
- Sarclisa new use OrphanOct 25, 2024
- Sarclisa new use Priority reviewOrphanSep 20, 2024
- Kevzara new use Jun 10, 2024
Drugs in development (43)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- AmlitelimabSAR445229Phase 39 trials
Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- PCV21 vaccinePhase 35 trials
Sanofi · Pneumococcal Immunization, Healthy Volunteers
- SAR445088Riliprubart, BIVV020Phase 35 trials
Sanofi · Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic, Transplant Rejection
- VenglustatGZ402671Phase 35 trials
Sanofi · Fabry Disease, Gaucher's Disease Type III, Gaucher Disease Type 1
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- MenACYW conjugate vaccineNimenrixPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunisation, Meningococcal Immunization
- BIVV001efanesoctocog, AltuvoctPhase 33 trials
Swedish Orphan Biovitrum · Haemophilia A (Moderate or Severe), Hemophilia A, Hemophilia A, Severe
- bypassing agentsClotting factor concentrates, CFCPhase 33 trials
Sanofi · Hemophilia, Von Willebrand Disease, Type 3
- M-M-R II vaccinePhase 33 trials
Sanofi · Pneumococcal Immunization
- MRI contrast-enhancing agentsPhase 33 trials
Sanofi · Multiple Sclerosis
- poliomyelitis vaccinePhase 33 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Whooping Cough, Diphtheria
- TolebrutinibSAR442168Phase 33 trials
Sanofi · Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- calcineurin inhibitorsPhase 32 trials
Sanofi · Dermatitis Atopic
- HexaximHexaxim Vaccine, DTaP-IPV-Hib-HepB vaccinePhase 32 trials
Sanofi · Pneumococcal Immunization, Meningococcal Immunisation, Healthy Volunteers
- IIV-HDstandalonePhase 32 trials
Sanofi · COVID-19 Immunization, Influenza Immunization, Immunization
- MRI contrast-enhancing preparationsPhase 32 trials
Sanofi · Multiple Sclerosis
- NVXC19EU licensed, standalonePhase 31 trial
Sanofi · Immunization, Healthy Volunteers, COVID-19 Immunization
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- EvorpaceptALX148Phase 25 trials
ALX Oncology Inc. · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Metastatic
- ADG126Phase 23 trials
Adagene Inc · Advanced/Metastatic Solid Tumors, Solid Tumor, Advanced Liver Cancers
- Antithymocyte globulinATGPhase 22 trials
Sanofi · Transplant Rejection, Renal Transplantation
Recruiting Phase 3 trials
Largest first.
- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07890454 · 6,000 participants (planned) · Start Oct 28, 2026 · Primary completion Dec 28, 2027
Drug: IIV-HD (standalone); NVXC19 (EU licensed, standalone) and 2 more · For: Immunization; Healthy Volunteers; COVID-19 Immunization and 1 more
Sites: Wroclaw, Poland; Gdynia, Poland
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in ChinaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07710872 · 4,568 participants (planned) · Start Aug 22, 2026 · Primary completion Mar 13, 2028
Drug: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA); Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) · For: Meningococcal Infection; Healthy Volunteers
Sites: Huanggang, China; Jianli City, Jingzhou City, China; Jingxi, China · 8 sites in all
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07348692 · 2,195 participants (planned) · Start Jan 20, 2026 · Primary completion Jun 7, 2027
Drug: PCV21 vaccine; 20vPCV licensed vaccine · For: Pneumococcal Immunization; Healthy Volunteers
Sites: Fayetteville, Arkansas; Huntington Park, California; Los Angeles, California · 25 sites in all
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184996 · 980 participants (planned) · Start Oct 8, 2025 · Primary completion May 9, 2028
Drug: Duvakitug; Placebo · For: Ulcerative Colitis
Sites: Peoria, Arizona; Scottsdale, Arizona; Tucson, Arizona · 240 sites in all
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184931 · 980 participants (planned) · Start Oct 1, 2025 · Primary completion May 14, 2029
Drug: Duvakitug; Placebo · For: Crohn's Disease
Sites: Peoria, Arizona; Scottsdale, Arizona; Tucson, Arizona · 461 sites in all
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07190222 · 942 participants (planned) · Start Sep 17, 2025 · Primary completion Nov 27, 2029
Drug: Lunsekimig; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 314 sites in all
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07190209 · 942 participants (planned) · Start Sep 16, 2025 · Primary completion Nov 27, 2029
Drug: Lunsekimig; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Chandler, Arizona; Phoenix, Arizona; Surprise, Arizona · 322 sites in all
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07185009 · 751 participants (planned) · Start Jan 16, 2026 · Primary completion Sep 21, 2028
Drug: Duvakitug; Placebo · For: Ulcerative Colitis
Sites: Tucson, Arizona; Coronado, California; Murrieta, California · 171 sites in all
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184944 · 751 participants (planned) · Start Jan 22, 2026 · Primary completion Aug 13, 2029
Drug: Duvakitug; Placebo · For: Crohn's Disease
Sites: Colorado Springs, Colorado; Kissimmee, Florida; Miami, Florida · 109 sites in all
- A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07088068 · 723 participants (planned) · Start Aug 6, 2025 · Primary completion Jun 6, 2028
Drug: Teplizumab · For: Type 1 Diabetes Mellitus
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 201 sites in all
Marketed drugs (43)
Newest FDA action first.
- Rifadin Rifampin · 1989
- Avapro Irbesartan · 1997
- Sarclisa Escena Isatuximab-Irfc · 2026
- Sarclisa Isatuximab-Irfc · 2020
- Soliqua 100/33 Insulin Glargine, Lixisenatide · 2016
- Adlyxin Lixisenatide · 2016
- Aubagio Teriflunomide · 2012
- Primaquine Primaquine Phosphate · 1952
- Priftin Rifapentine · 1998
- Caprelsa Vandetanib · 2011
- Rezurock Belumosudil Mesylate · 2021
- Cerezyme Imiglucerase · 1994
- Wayrilz Rilzabrutinib · 2025
- Avalide Hydrochlorothiazide, Irbesartan · 1997
- Qfitlia Fitusiran Sodium · 2025
- Merilog Insulin Aspart-Szjj · 2025
- Lumizyme Alglucosidase Alfa · 2010
- Xenpozyme Olipudase Alfa-Rpcp · 2022
- Fexinidazole Fexinidazole · 2021
- Toujeo Solostar Insulin Glargine Recombinant · 2015
- Fabrazyme Agalsidase Beta · 2003
- Arava Leflunomide · 1998
- Kevzara Sarilumab · 2017
- Lemtrada Alemtuzumab · 2001
- Renagel Sevelamer Hydrochloride · 2000
- Zaltrap Ziv-Aflibercept · 2012
- Multaq Dronedarone Hydrochloride · 2009
- Mozobil Plerixafor · 2008
- Nexviazyme Avalglucosidase Alfa-Ngpt · 2021
- Plavix Clopidogrel Bisulfate · 1997
- Admelog Insulin Lispro · 2017
- Lovenox (Preservative Free) Enoxaparin Sodium · 1993
- Jevtana Kit Cabazitaxel · 2010
- Lantus Solostar Insulin Glargine Recombinant · 2000
- Taxotere Docetaxel · 1996
- Apidra Solostar Insulin Glulisine Recombinant · 2004
- Ferrlecit Sodium Ferric Gluconate Complex · 1999
- Thyrogen Thyrotropin Alfa · 1998
- Myozyme Alglucosidase Alfa · 2006
- Elitek Rasburicase · 2002
- Cerdelga Eliglustat Tartrate · 2014
- Diabeta Glyburide · 1984
- Lovenox Enoxaparin Sodium · 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.